electroCore (ECOR) Earnings Date & Reports

Key Takeaways

• electroCore reported third quarter 2026 net sales of approximately $9.7 million, up about 12% year over year, though below the roughly $10.9 million consensus revenue estimate.
• Net loss narrowed to $1.3 million, or $0.13 per share, from $3.4 million, or $0.40 per share, a year earlier — beating the consensus estimate of a $0.26 per-share loss.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) loss improved 67% year over year to $0.7 million, its lowest level on record, with gross margin expanding to 88.5%.
• Full-year 2026 revenue guidance was revised to a range of $39 million to $42 million, while preliminary 2027 guidance calls for 30% to 40% growth and a first quarter of positive Adjusted EBITDA by the end of 2027.
• Cash, cash equivalents, and marketable securities totaled approximately $7.5 million at September 30, 2026.
• For additional context on ECOR, explore its Major News, Today's Price Move, Price Targets, and Forecast pages.
• Discover automated trade ideas and market scanning strategies with Trending AI Robots.

Earnings Context and Why It Matters

electroCore is a commercial-stage bioelectronic medicine company whose prescription portfolio — led by gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell Fibromyalgia — is increasingly anchored in U.S. Department of Veterans Affairs (VA) sales. The third quarter report matters because it tests whether the company can convert a fast-expanding federal sales channel into structurally better profitability. Coming off back-to-back record revenue quarters, investors were watching whether narrower losses and expanding gross margins would continue, and whether management's updated guidance would signal a credible, lower-cost path toward breakeven. The results carry added weight given the company's limited cash position and its stated goal of reaching positive Adjusted EBITDA without a new dilutive equity raise.

Reported Results

For the three months ended September 30, 2026, electroCore reported net sales of approximately $9.7 million, a roughly 12% increase from $8.7 million in the prior-year period. Growth was driven primarily by Quell Fibromyalgia and prescription gammaCore sales into the VA channel. Revenue came in below the approximately $10.9 million consensus estimate, while the company's loss per share of $0.13 was narrower than the $0.26 per-share loss analysts had expected.

Gross profit rose to $8.6 million, lifting gross margin to 88.5% from 86.0% a year earlier and 86.5% in the second quarter, reflecting favorable product mix. Operating expenses declined modestly to $10.1 million from $10.4 million a year ago. GAAP (generally accepted accounting principles) net loss was $1.3 million, or $0.13 per share, compared with $3.4 million, or $0.40 per share, in the third quarter of 2025. The quarter benefited from a non-recurring gain of about $0.4 million in other income related to an indemnification settlement.

Adjusted EBITDA loss narrowed to $0.7 million from $2.0 million a year earlier, an improvement of about 67%. Management revised full-year 2026 revenue guidance to $39 million to $42 million, from prior guidance of more than 30% growth, and introduced preliminary 2027 revenue growth guidance of 30% to 40%, with an expectation of achieving its first quarter of positive Adjusted EBITDA by the end of 2027.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking events such as electroCore's quarterly earnings, the AI Screener offers a structured way to identify comparable opportunities across the market.

Market Reaction and Investor Sentiment

Investor focus around this report centered less on the modest revenue miss and more on the sharp improvement in profitability and the updated pathway toward Adjusted EBITDA breakeven. The record-low loss from operations and 88.5% gross margin reinforced management's message that revenue growth is increasingly translating into bottom-line improvement. Still, sentiment carries a degree of caution: with roughly $7.5 million in cash and marketable securities at quarter-end, questions about funding runway and the pace of cash burn remain central to how the market interprets the results.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will likely focus on whether the company can deliver against its revised 2026 revenue range of $39 million to $42 million while continuing to narrow losses. The shift of VA prescription sales through the Lovell distribution agreement is expected to reduce transaction fees and free internal resources for new market development, a dynamic worth monitoring in the fourth quarter and into 2027.

Preliminary 2027 guidance of 30% to 40% revenue growth — and a first quarter of positive Adjusted EBITDA by the end of 2027 — sets a clear benchmark, but achieving it depends on sustained VA account expansion, faster new-representative productivity, and improved patient refill rates. Management has highlighted a national refill rate of 42% year to date, with a stated goal above 70%, making refill trends a key leading indicator.

Other factors to watch include potential label expansion for Quell for chemotherapy-induced peripheral neuropathy, which remains subject to FDA (U.S. Food and Drug Administration) clearance, as well as the company's cash position and any future financing decisions. Progress on these fronts will shape whether electroCore can maintain its improved margin profile while scaling revenue across its federal and commercial channels.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations